Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

Annals of Oncology

Volumn 15, Issue 5, 2004, Pages 821-830

  Tobinai, K ^a   Igarashi, T ^b   Itoh, K ^b   Kobayashi, Y ^a   Taniwaki, M ^c   Ogura, M ^d   Kinoshita, T ^e   Hotta, T ^f   Aikawa, K ^g   Tsushita, K ^h   Hiraoka, A ⁱ   Matsuno, Y ^a   Nakamura, S ^d   Mori, S ^j   Ohashi, Y ^j   Nakata, Y ^g   Kasai, M ^k   Kiyama, Y ^k   Kano, Y ^l   Akutsu, M ^l   Miwa, T ^m   Takesako, N ^m   Watanabe, T ^a   Ohyashiki, K ⁿ   Tauchi, T ⁿ   Sasao, T ^f   Ohnishi, K ^o   Morishima, Y ^d   Kagami, Y ^d   Murate, T ^h   Nagai, H ^h   Hirano, M ^p   Okamoto, M ^p   Kageyama, S ^q   Yamaguchi, M ^c   Ohno, H ^r   Ishikawa, T ^r   Suzuki, T ^s   Karasuno, T ^t   Murayama, T ^u   Sakai, A ^v   Uike, N ^w   Maeda, T ^x   Tsukasaki, K ^x   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HOKKAIDO CANCER CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k SAPPORO HOKUYU HOSPITAL   (Japan)

^l TOCHIGI CANCER CENTER   (Japan)

^m International Medical Center   (Japan)

ⁿ TOKYO MEDICAL UNIVERSITY   (Japan)

^o HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r KYOTO UNIVERSITY   (Japan)

^s Shiga Medical Center for Adults   (Japan)

^t Department of Cancer Control and Statistics   (Japan)

^u HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^v HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^w NATIONAL KYUSHU CANCER CENTER   (Japan)

^x NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Aggressive B cell lymphoma; Pharmacokinetics; Prognostic factor; Rituximab

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BACKACHE; BLOOD TOXICITY; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE ACTIVITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; JAPAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PRURITUS; REFRACTORY PERIOD; RESPIRATORY TRACT DISEASE; RHINORRHEA; SKIN DISEASE; SWEATING; TACHYCARDIA; THIRST; THROAT DISEASE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 2642510885     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh176     Document Type: Article

References (31)

1. Kadin ME, Berard CW, Nanba K et al. Lymphoproliferative diseases in Japan and western countries. Proceedings of the United States-Japan Seminar, September 6 and 7, 1982, Seattle, Washington. Human Pathol 1983; 14: 745-772.
2. Izumo T, Maseki N, Mori S et al. Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas. Jpn J Cancer Res 2000; 91: 351-360.
3. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
4. Ohshima K, Suzumiya J, Sato K et al. B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. Cancer Lett 1999; 135: 73-81.
5. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349.
6. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
7. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
8. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
9. Igarashi T, Kobayashi Y, Ogura M et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoina treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13: 928-943.
10. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
11. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
12. Vose JM, Link BK, Grossbard M et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
13. Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 1998; 9: 527-534.
14. Nguyen DT, Amess JA, Doughty H et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76-82.
15. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
16. Stashenko P, Nadler LM, Hardy R et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1685.
17. Mason DY, Comans-Bitter W, Cordell JL et al. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215-1222.
18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
19. Banno S, Yoshikawa K, Nakamura S et al. Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus. Jpn J Cancer Res 1994; 85: 918-926.
20. Nakamura S, Seto M, Banno S et al. Immunohistochemical analysis on the cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. Jpn J Cancer Res 1994; 85: 1270-1279.
21. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol 1993; 23: 250-257.
22. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
23. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274.
24. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244-1253.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
28. Tsuda F, Okamoto H, Ukita M et al. Determination of antibody to TT virus (TTV) and application to blood donois and patients with post-transfusion non-A to G hepatitis in Japan. J Virol Method 1999; 77: 199-206.
29. Nishizawa T, Okamoto H, Konishi K et al. A novel DNA virus (TTV) associated with elevated transaminase levels in post-transfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997; 241: 92-97.
30. Tsai DE, Moore HCF, Hardy CL et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 521-526.
31. Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.